cabotegravir oral
Selected indexed studies
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (N Engl J Med, 2020) [PMID:32130806]
- Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. (Lancet HIV, 2023) [PMID:37952550]
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (N Engl J Med, 2021) [PMID:34379922]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (2023) pubmed
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) pubmed
- HIV Pre-Exposure Prophylaxis. (2024) pubmed
- Optimising oral PrEP while awaiting long-acting cabotegravir. (2023) pubmed
- Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. (2023) pubmed
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. (2022) pubmed
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (2020) pubmed
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. (2020) pubmed
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. (2021) pubmed
- Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis. (2023) pubmed